Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2022 Earnings Conference Call March 23, 2023 5:00 PM ET

Company Participants

Susan Pietropaolo - Managing Director

William Rice - Chairman, President and CEO

Fletcher Payne - SVP and Chief Financial Officer

Rafael Bejar - SVP and Chief Medical Officer

Conference Call Participants

Matthew Biegler - Oppenheimer

Soumit Roy - Jones Trading

Joe Pantginis - H.C. Wainwright

Edward Tenthoff - Piper Sandler

Operator

Hello and thank you for standing by and welcome to Aptose Biosciences reports for the Fourth Quarter and Yearend 2022 Conference Call.

At this time, all participants on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator instructions]

I will now like to hand the conference over to Susan Pietropaolo. You may begin.

Susan Pietropaolo

Thank you, Towanda. Good afternoon and welcome to the Aptose Biosciences conference call to discuss financial and operational results for the yearend and fourth quarter ending December 31, 2022. Earlier today, Aptose issued a press release relating to these financial results. The news release as well as related SEC filings are accessible on Aptose website.

Joining me on today's call are Dr. William G. Rice Chairman, President and CEO, Dr. Rafael Bejar, Senior Vice President and Chief Medical Officer and Mr. Fletcher Payne, Senior Vice President and Chief Financial Officer.

Before we proceed, I'd like to remind everyone that certain statements made during this call will include forward-looking statements within the meaning of US and Canadian Securities Laws. Forward-looking statements reflect Aptose's current expectations regarding future events. They are not guarantees of performance and it is possible that actual results and performance could differ materially from these stated expectations. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed. To learn more about these risks and uncertainties, please read the risk factors set forth in Aptose's most recent annual report on Form 10-K and SEC and SEDAR filings.. All forward-looking statements made during this call speak only as of the date they're made. Aptose undertakes no obligation to revise or update these statements to reflect events or circumstances after the date of this call, except as required by law.

I'll now turn the call over to Dr. Rice, Chairman, President and CEO of Aptose Biosciences, Dr. Rice?

William Rice

Thank you, Susan. I want to welcome everyone to our call for the yearend and fourth quarter ended December 31, 2022. First, I'll provide a very quick overview of 2022. While the biotech market has been extraordinarily challenging, Aptose continued a steady march forward. We extended our cash runway to the end of Q1 2024. We continued building a talented and experienced team. We created and began testing a new formulation for Luxceptinib and most importantly, we made significant strides in the development of Tuspetinib for the treatment of acute myeloid leukemia or AML.